76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12

June 8, 2012

Data from a Phase IIb study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, show that 76% of patients with active rheumatoid arthritis (RA) receiving either 4mg or 8mg of baricitinib, an oral JAK1/JAK2 inhibitor, plus stable methotrexate (MTX) achieved ACR20* response compared with 41% of placebo-treated patients (p≤0.001) at 12 weeks. The 4mg and 8mg doses of baricitinib demonstrated statistical superiority to placebo in all clinical outcomes measured, including ACR20/50/70*, DAS28**-CRP and DAS28-CRP <2.6. Adverse events (AEs) were mild and no new safety signals were reported, according to the study authors.

Results of the 12-week primary endpoint analysis conducted in 301 with moderate to severe RA and inadequate responses to MTX demonstrate that 35% and 23% of patients taking the 4mg achieved ACR50/70 responses respectively; 40% and 20% of patients taking the 8mg dose achieved ACR50/70, compared to 10% and 2% in the placebo groups respectively. Greater proportions of patients achieved disease remission as judged by the DAS28-CRP <2.6 in the 4mg (37%) and 8mg (22%) dose groups compared to placebo (4%) (p≤0.001). Furthermore, of patients receiving the 4mg or 8mg doses, 60% and 67% respectively achieved the minimum clinically important difference (MCID***) for the HAQ-DI**** compared to placebo (41%) at week 12.

"The JAK1/JAK2 signalling pathway has been shown to be important in the pathobiology of RA and no other JAK1/JAK2 inhibitor treatments have yet been approved for the treatment of RA," said Dr Edward Keystone, University of Toronto, Canada and lead author of the study. "There is still a large proportion of patients that have inadequate responses to currently approved treatments for RA and baricitinib could represent a new, viable treatment option for this group of patients. The results of this study would suggest that the compound appears worthy of future Phase III investigation."

According to the researchers, onset of efficacy was rapid for ACR20, ACR50, ACR70, and DAS28-CRP, with statistically significant differences seen after two weeks of therapy. Dose dependent decreases in hemoglobin, small increases in serum creatinine, and increases in low-density lipoprotein (LDL) cholesterol and high-density lipoprotein (HDL) cholesterol were seen. Patients were randomized to receive either placebo or one of four once-daily doses (1, 2, 4, or 8mg) for 12 weeks. The study population was 83% female, with a mean age of 51 years and a mean duration of RA of five to seven years.

Whilst the majority of AEs reported were mild, there were seven serious AE's reported in six patients (two events in the placebo group, four in the 2mg group, one in the 8 mg group). No deaths or opportunistic infections occurred in the active treatment groups. One patient in the placebo group was diagnosed with an opportunistic infection of toxocariasis. A similar rate of infection was observed in the group (12%) and the combined treatment groups (14%), representing the most common treatment emergent AE.

Explore further: Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo

More information: Abstract Number: LB0005

*ACR (American College of Rheumatology) criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate), patient assessment, physician assessment, pain scale and disability/functional questionnaire. ACR20 refers to a 20% improvement in tender/swollen joint counts, as well as three of the five other criteria. ACR50 refers to a 50% improvement and ACR70 refers to a 70% improvement.

**DAS28 (Disease Activity Score) is an index used by physicians to measure how active an individual's RA is. It assesses number of tender and swollen joints (out of a total of 28), levels of C-reactive protein (CRP, a protein found in the blood, the levels of which rise in response to inflammation), and the patient's 'global assessment of global health'. A higher score indicates more active disease. A score of <2.6 indicates that the patient is in remission.

***MCID (Minimum clinically important difference) represents the smallest improvement in disease considered worthwhile by a patient.

****HAQ DI (Health Assessment Questionnaire – Disease Index) is a patient questionnaire that measures function and health-related quality of life through measuring a patient's ability to perform everyday tasks.

Related Stories

Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo

June 8, 2012
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than ...

Tocilizumab is more effective than adalimumab at reducing signs and symptoms of rheumatoid arthritis

June 6, 2012
Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis ...

Patients taking certolizumab pegol are twice as likely to achieve ACR20 compared to placebo

June 7, 2012
A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients treated with certolizumab pegol (CZP) were twice as likely to meet the primary endpoint ...

Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA

May 25, 2011
Data presented today at the EULAR 2011 Annual Congress demonstrated that initial treatment with adalimumab (Humira, ADA) plus methotrexate in early RA patients can provide high levels of disease control in many patients, ...

Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab

June 7, 2012
Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving ...

Recommended for you

Study shows prevalence of knee osteoarthritis has doubled since World War II

August 14, 2017
The average American today is twice as likely to be diagnosed with knee osteoarthritis than in the years before World War II, Harvard scientists say, but that increase can't be blamed on the reasons most might think.

Researchers find arthritis drug could treat blood cancer patients

August 3, 2017
Blood cancer sufferers could be treated with a simple arthritis drug, scientists at the University of Sheffield have discovered.

Fluid in the knee holds clues for why osteoarthritis is more common in females

June 26, 2017
Researchers have more evidence that males and females are different, this time in the fluid that helps protect the cartilage in their knee joints.

Biologics before triple therapy not cost effective for rheumatoid arthritis

May 29, 2017
Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). ...

Drug for refractory psoriatic arthritis shows promise in clinical trial

May 24, 2017
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced ...

Cross-species links identified for osteoarthritis

May 17, 2017
New research from the University of Liverpool, published today in the journal npj Systems Biology and Applications, has identified 'cell messages' that could help identify the early stages of osteoarthritis (OA).


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.